SFTPB, surfactant protein B, 6439

N. diseases: 108; N. variants: 11
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0032285
Disease: Pneumonia
Pneumonia
0.070 GeneticVariation disease BEFREE Regulatory Roles of Human Surfactant Protein B Variants on Genetic Susceptibility to Pseudomonas Aeruginosa Pneumonia-Induced Sepsis. 31851120 2019
CUI: C0032285
Disease: Pneumonia
Pneumonia
0.070 AlteredExpression disease BEFREE The effects of Nampt in the pulmonary epithelial cell on both SFTPB expression and lung inflammation were investigated in a LPS-induced ALI mouse model. 29452569 2018
CUI: C0032285
Disease: Pneumonia
Pneumonia
0.070 GeneticVariation disease BEFREE We conclude that mice with SP-B-C allele are more susceptible to S. aureus pneumonia than mice with SP-B-T allele, and that CMC2.24 attenuates lung injury thus reducing mortality. 26863117 2016
CUI: C0032285
Disease: Pneumonia
Pneumonia
0.070 GeneticVariation disease BEFREE Previous studies have indicated that a SP-B 1580C/T polymorphism (SNP rs1130866) was associated with lung diseases including pneumonia. 26620227 2016
CUI: C0032285
Disease: Pneumonia
Pneumonia
0.070 Biomarker disease BEFREE SP-B deficiency was associated with lung inflammation and increased soluble L-selectin, STAT-3, and phosphorylated STAT-3 in alveolar macrophages and alveolar epithelial cells. 16024721 2005
CUI: C0032285
Disease: Pneumonia
Pneumonia
0.070 GeneticVariation disease BEFREE Women with the variant SP-B polymorphism also had significantly increased odds of having a direct pulmonary injury such as aspiration or pneumonia as a risk factor for ARDS as opposed to an indirect pulmonary risk for ARDS (OR, 4.6; 95% CI, 1.1 to 19.9; p = 0.04). 14718442 2004
CUI: C0032285
Disease: Pneumonia
Pneumonia
0.070 AlteredExpression disease BEFREE The highest expressing line (line 28) demonstrated reduced lung inflammation and edema, reduced lung wet-to-dry weight ratios, decreased bronchoalveolar lavage (BAL) protein and neutrophils, reduced interleukin (IL)-1beta, interleukin-6, and macrophage inflammatory protein-2, and maintained surfactant protein-B (SP-B) levels compared with nontransgenic controls. 11919079 2002